Implantation of embryonic stem cells (ESC)-derived insulin-producing cells has been extensively investigated for treatment of @entity6 in animal models. However, the in vivo behavior and migration of transplanted cells in @entity6 models remains unclear. Here we investigated the location and migration of insulin-producing cells labeled with superparamagnetic @entity1933 (SPIO) using a dynamic MRI tracking method. SPIO labeled cells showed hypointense signal under the kidney subcapsules of @entity6 @entity19 on MRI, and faded gradually over the visiting time. However, new hypointense signal appeared in the spleen 1 week after transplantation, and became obvious with the time prolongation. Further histological examination proved the immigrated cells were insulin and C-peptide positive cells which were evenly distributed throughout the spleen. These intra-spleen insulin-producing cells maintained their protective effects against @entity4854 in vivo, and these effects were reversed upon spleen removal. Transplantation of insulin-producing cells through spleen acquired an earlier blood @entity413 control as compared with that through kidney subcapsules. In summary, our data demonstrate that insulin-producing cells transplanted through kidney subcapsules were not located in situ but migrated into spleen, and rescues @entity4854 in @entity6 models. MRI may provide a novel tracking method for preclinical cell transplantation therapy of @entity6 continuously and non-invasively.

Insulin-producing cells from embryonic stem cells rescues XXXX via intra-spleen migration.

@entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity1933 :: ('MESH:C000499', 'Chemical') :: ['iron oxide'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity4854 :: (MESH:D006943,Disease) :: ['hyperglycemia']
